EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Ursolic Acid Ameliorates Diabetic Nephropathy by Inhibiting JAK2/STAT3-Driven Ferroptosis: Mechanistic Insights from Network Pharmacology and Experimental Validation

Yijing Zhou, Chengli Lou, Xiuqin Xu, Bo Feng iD, Xiaoping Fan, Xiangjing Wang

Drug Design, Development and Therapy · 2025-08 · Volume 19 · 6699-6717

DOI: 10.2147/dddt.s526554 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2025-08. Verfasst von Yijing Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephropathy, Jiaxing Traditional Chinese Medicine Hospital, Jiaxing, People's Republic of China. Hauptthemen laut MEDLINE: Janus Kinase 2, STAT3 Transcription Factor, Triterpenes, Diabetic Nephropathies. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Ursolic acid (UA) improves diabetic nephropathy (DN), but its regulatory mechanism requires further verification.

Methods

The bioactive component-target network of UA in DN was determined using a network pharmacology approach. DN mice (STZ-diabetic C57BL/6 mice, n = 8/group, 4 weeks) were treated with UA (25 mg/kg and 100 mg/kg) and the JAK agonist RO8191 (2 mg/kg). The DN cell model (high glucose-injured NRK-52E cells) was treated with UA (10 and 50 µM) and RO8191 (2 μM) for 24 h. The molecular mechanisms by which UA acts were further verified in vivo and in vitro.

Results

UA treatment ameliorated the general state of the DN mouse model, as characterized by the attenuation of weight loss and downregulation of fasting blood glucose (FBG) and fasting serum insulin (FINS) levels (all P < 0.05). Renal pathological changes and impaired renal function (increased levels of Scr, BUN, and UAER) were also improved by UA treatment (all P < 0.05). In vitro, UA increased the viability of DN cells in vitro (P < 0.001). Concurrently, UA remarkably downregulated the levels of ROS, SOD, and iron and up-regulated the levels of MDA, GPX4, and SLC7A11 (all P < 0.05) in vivo and in vitro. Mechanistically, activation of the JAK2-STAT3 pathway with the agonist RO8191 significantly reduced UA's anti-ferroptosis and anti-oxidative effects of UA.

Conclusion

UA protected against DN by blocking JAK2/STAT3-mediated ferroptosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase 2STAT3 Transcription FactorTriterpenesDiabetic NephropathiesFerroptosisDiabetes Mellitus, ExperimentalAnimalsUrsolic AcidMice, Inbred C57BLMiceNetwork PharmacologyMaleStreptozocinDose-Response Relationship, DrugRatsStructure-Activity RelationshipCells, CulturedMolecular Structure

Stichwörter der Autor:innen

JAK2/STAT3 pathwaydiabetic nephropathyferroptosisnetwork pharmacologyursolic acid

Substanzen

Janus Kinase 2STAT3 Transcription FactorTriterpenesUrsolic AcidJak2 protein, mouseStat3 protein, mouseStreptozocin

Autor:innen und Institutionen

  • Department of Nephropathy, Jiaxing Traditional Chinese Medicine Hospital, Jiaxing, People's Republic of China.

ORCID-Profile: Bo Feng

Zitieren

APA

Zhou, Y., Lou, C., Xu, X., Feng, B., Fan, X., & Wang, X. (2025). Ursolic Acid Ameliorates Diabetic Nephropathy by Inhibiting JAK2/STAT3-Driven Ferroptosis: Mechanistic Insights from Network Pharmacology and Experimental Validation. Drug Design, Development and Therapy, Volume 19, 6699-6717. https://doi.org/10.2147/dddt.s526554

Vancouver

Zhou Y, Lou C, Xu X, Feng B, Fan X, Wang X. Ursolic Acid Ameliorates Diabetic Nephropathy by Inhibiting JAK2/STAT3-Driven Ferroptosis: Mechanistic Insights from Network Pharmacology and Experimental Validation. Drug Design, Development and Therapy. 2025;Volume 19:6699-6717. doi:10.2147/dddt.s526554

BibTeX
@article{Zhou2025,
  author = {Zhou, Yijing and Lou, Chengli and Xu, Xiuqin and Feng, Bo and Fan, Xiaoping and Wang, Xiangjing},
  title = {Ursolic Acid Ameliorates Diabetic Nephropathy by Inhibiting JAK2/STAT3-Driven Ferroptosis: Mechanistic Insights from Network Pharmacology and Experimental Validation},
  journal = {Drug Design, Development and Therapy},
  year = {2025},
  volume = {Volume 19},
  pages = {6699--6717},
  doi = {10.2147/dddt.s526554}
}
Kostenlos starten →